3
Announcements
Trials
Browse
Landscape
Status
Recruiting
3
Active not recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
7
Somatostatinoma
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Somatostatin Receptor-positive GEP-NET
1
Small Cell Lung Carcinoma
1
Neuroblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
1
lutetium Lu 177 dotatate
1
lanreotide
1
arginyllysine
1
Resveratrol
1
PM 01183
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Etoposide
1
Cryotherapy
1
Carboplatin
1
Acupuncture Therapy
1
Acupressure
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastro-enteropancreatic neuroendocrine tumor
×
lutetium Lu 177 dotatate
×
Clear all
NCT04727723
2026-05-04
REAL-LU
Novartis
Completed
164 enrolled